Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration.
Radium-223 in mCPRC patients: a large real-life Italian multicenter study / Frantellizzi, Viviana; Monari, Fabio; Mascia, Manlio; Costa, Renato P; Rubini, Giuseppe; Spanu, Angela; Farcomeni, Alessio; Lodi Rizzini, Elisa; Cindolo, Luca; Tripoli, Vincenzo; Lavelli, Valentina; Nuvoli, Susanna; Pontico, Mariano; Dionisi, Valeria; Ferrari, Cristina; De Vincentis, Giuseppe. - In: MINERVA UROLOGY AND NEPHROLOGY. - ISSN 2724-6442. - Volume 74, Issue 1, Pages 21 - 28 February 2022:(2022). [10.23736/S2724-6051.20.03808-4]
Radium-223 in mCPRC patients: a large real-life Italian multicenter study
Spanu, Angela;Nuvoli, Susanna;
2022-01-01
Abstract
Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration.| File | Dimensione | Formato | |
|---|---|---|---|
|
2022.Minerva Urology Nephrology. Ra223.pdf
solo utenti autorizzati
Tipologia:
Versione editoriale (versione finale pubblicata)
Licenza:
DRM non definito
Dimensione
975.9 kB
Formato
Adobe PDF
|
975.9 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
